TESARO (TSRO) Receives News Sentiment Score of 0.13
News coverage about TESARO (NASDAQ:TSRO) has trended somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. TESARO earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.8110412811373 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Insider Selling: TESARO Inc (TSRO) SVP Sells 829 Shares of Stock (americanbankingnews.com)
- ETFs with exposure to TESARO, Inc. : December 5, 2017 (finance.yahoo.com)
- Overview on Beta Factor – Tesaro, Inc., (NASDAQ: TSRO) – Stock Watch (stocksnewstimes.com)
- Contrasting TESARO (TSRO) & Its Rivals (americanbankingnews.com)
- Tesaro Becomes Oversold (TSRO) – Nasdaq (nasdaq.com)
A number of research analysts recently commented on the company. Robert W. Baird restated a “neutral” rating and set a $125.00 price objective on shares of TESARO in a research note on Monday, October 2nd. Cann restated a “buy” rating and set a $199.00 price objective on shares of TESARO in a research note on Friday, September 8th. BidaskClub upgraded TESARO from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 23rd. Citigroup restated a “buy” rating and set a $216.00 price objective on shares of TESARO in a research note on Monday, September 11th. Finally, Oppenheimer restated a “buy” rating and set a $199.00 price objective on shares of TESARO in a research note on Sunday, September 10th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $159.39.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.69. The firm had revenue of $142.77 million for the quarter, compared to analyst estimates of $130.57 million. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. TESARO’s quarterly revenue was up 740.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.72) earnings per share. equities research analysts predict that TESARO will post -8.16 EPS for the current year.
In related news, SVP Martin H. Jr. Huber sold 829 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $85.24, for a total transaction of $70,663.96. Following the transaction, the senior vice president now directly owns 8,101 shares of the company’s stock, valued at $690,529.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James O. Armitage sold 10,000 shares of the company’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $117.13, for a total value of $1,171,300.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at $1,171,300. The disclosure for this sale can be found here. Insiders have sold 11,421 shares of company stock worth $1,312,175 over the last three months. 34.60% of the stock is owned by insiders.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Stock Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related stocks with our FREE daily email newsletter.